Natera, Inc. (NASDAQ:NTRA) Shares Bought by Gordian Capital Singapore Pte Ltd

Gordian Capital Singapore Pte Ltd raised its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 59.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 13,084 shares of the medical research company's stock after acquiring an additional 4,891 shares during the period. Natera makes up 1.1% of Gordian Capital Singapore Pte Ltd's investment portfolio, making the stock its 18th largest holding. Gordian Capital Singapore Pte Ltd's holdings in Natera were worth $2,071,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in NTRA. Principal Securities Inc. lifted its position in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares during the period. Gladstone Institutional Advisory LLC increased its stake in Natera by 1.7% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock valued at $574,000 after purchasing an additional 61 shares in the last quarter. Silver Oak Securities Incorporated raised its holdings in Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock worth $470,000 after purchasing an additional 89 shares during the last quarter. Colonial Trust Co SC boosted its position in Natera by 7.8% during the fourth quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock worth $210,000 after purchasing an additional 96 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Trading Down 2.2%

Shares of NTRA stock opened at $151.09 on Thursday. The firm's 50-day simple moving average is $149.18 and its 200-day simple moving average is $157.11. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00. The firm has a market cap of $20.63 billion, a P/E ratio of -85.85 and a beta of 1.79.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera's revenue for the quarter was up 36.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.56) earnings per share. As a group, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on NTRA. The Goldman Sachs Group lifted their target price on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Royal Bank of Canada began coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. BTIG Research restated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Finally, Barclays increased their price objective on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus target price of $182.12.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the sale, the chief executive officer now owns 203,354 shares in the company, valued at $29,160,963.60. This trade represents a 30.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gail Boxer Marcus sold 4,000 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $151.61, for a total transaction of $606,440.00. Following the completion of the transaction, the director now owns 9,704 shares of the company's stock, valued at $1,471,223.44. This trade represents a 29.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 152,436 shares of company stock valued at $22,019,079. Company insiders own 7.60% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.